CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


Last Updated: July 12, 2007
Result type: Reports
Project Number: SR0098-000
Product Line: Reimbursement Review

Generic Name: Ranibizumab

Brand Name: Lucentis

Manufacturer: Novartis Pharmaceuticals Inc.

Therapeutic Area: Macular degeneration, age-related

Indications: Macular degeneration, age-related

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: March 27, 2008

Recommendation Type: List with clinical criteria and/or conditions